Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreem ...

Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced t ...

Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature Communications demonstrating the world’s ...

Eli Lilly will take the baton on developing a peripheral pain candidate from Confo Therapeutics, handing off $40 million upfront and a potential $590 million total down the track if all goes well ...

Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer GHENT, Belgium-- (BUSINESS WIRE)-- Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled ...

Eli Lilly sees potential in the non-opioid pain drug research from Confo Therapeutics and it’s paying $40 million for rights to the biotech’s most advanced program. The sum is an upfront payment.

Confo Therapeutics’ business development team is on a roll. Weeks after licensing its lead candidate to Eli Lilly, the Belgian biotech has landed a 168 million euro ($182 million) deal with ...

Confo Therapeutics, a Belgian firm developing small molecules and antibodies that target G protein–coupled receptors, aims to start testing its drug candidates in humans with the help of $65 ...

Profile The positions in the table below reflect the Confo Therapeutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position ...

Co-founded by Professor Steyaert, Confo Therapeutics utilizes the Confo technology which consists of single domain antibodies that transform unstable GPCRs into stable functional conformations ...

GHENT, Belgium, July 26, 2024--Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a ...

GHENT, Belgium, October 01, 2024--Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature ...